Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: IMARC | PRODUCT CODE: 1206631

Cover Image

PUBLISHER: IMARC | PRODUCT CODE: 1206631

Oncolytic Virus Therapies Market by Virus Type (Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses), Application (Solid Tumors, Melanoma), End Use (Hospitals, Specialty Clinics, Cancer Research Institute), and Region 2023-2028

PUBLISHED:
PAGES: 143 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 2499
PDF & Excel (5 User License)
USD 3499
PDF & Excel (Corporate License)
USD 4499

Add to Cart

The global oncolytic virus therapies market size reached US$ 130.4 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 492.6 Million by 2028, exhibiting a growth rate (CAGR) of 20.90% during 2023-2028.

Oncolytic virus therapies are a form of immunotherapy that utilizes viruses to infect and destroy cancer cells. They use various natural and genetically modified viruses, such as herpes simplex, Newcastle disease, vaccinia, adenovirus, reovirus, and picornavirus. Oncolytic virus therapies activate danger signals for generating an immune response and are widely used for treating solid tumors, melanoma, and unresectable lesions. They also help eradicate tumors using viruses that only infect and destroy targeted tumor cells. As compared to chemotherapy, oncolytic virus therapies are non-toxic, provide superior efficacy, and prolong the survival of cancer patients. As a result, they find extensive applications in hospitals, clinics, and cancer research institutes.

Oncolytic Virus Therapies Market Trends:

  • The rising incidences of cancer across the globe are creating a positive outlook for the market. Oncolytic virus therapies are widely used to treat various cancers, such as glioblastoma, breast, lung, and prostate cancers, due to their powerful anti-tumor properties and ability to target tumors accurately without harming surrounding tissues. In line with this, the widespread utilization of the therapy to treat various types of melanomas, such as hematological malignancies, lymphoma, leukemia, and myeloma, is favoring the market growth. Furthermore, rising concerns among patients regarding the negative health impact of various cancer treatments, such as surgical intervention, radiotherapy, chemotherapy, and immunotherapy, are providing a considerable boost to the market growth. Additionally, the rising number of clinical studies in oncolytic viruses, such as herpesvirus, adenovirus, and vaccinia virus, that is in the final stages and have demonstrated excellent experimental results are facilitating the market growth. Other factors, including rising demand for advanced treatments and novel therapies and increasing initiatives by several governments to spread awareness regarding different causes of cancer and promote early diagnosis, are anticipated to drive the market growth.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global oncolytic virus therapies market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on virus type, application and end use.

Breakup by Virus Type:

  • Genetically Engineered Oncolytic Viruses
  • Herpes Simplex Virus
  • Adenovirus
  • Vaccinia Virus
  • Oncolytic Wild-Type Viruses
  • Reovirus
  • Newcastle Disease Virus
  • Vesicular Stomatitis Virus

Breakup by Application:

  • Solid Tumors
  • Breast Cancer
  • Prostate Cancer
  • Lung Cancer
  • Glioblastoma
  • Melanoma
  • Hematological Malignancies
  • Lymphoma
  • Leukemia
  • Myeloma

Breakup by End Use:

  • Hospitals
  • Specialty Clinics
  • Cancer Research Institute

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

  • The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Dnatrix Inc., Genelux Corporation, Lokon Pharma AB, Replimune Group Inc., Rigvir Ltd., Sorrento Therapeutics, Takara Bio Inc. (Takara Holdings Inc.), Targovax, TILT Biotherapeutics Ltd, Transgene SA and Vyriad. Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • 1. What was the size of the global oncolytic virus therapies market in 2022?
  • 2. What is the expected growth rate of the global oncolytic virus therapies market during 2023-2028?
  • 3. What are the key factors driving the global oncolytic virus therapies market?
  • 4. What has been the impact of COVID-19 on the global oncolytic virus therapies market?
  • 5. What are the key regions in the global oncolytic virus therapies market?
  • 6. Who are the key players/companies in the global oncolytic virus therapies market?
Product Code: SR1323A103_Report

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Oncolytic Virus Therapies Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Virus Type

  • 6.1 Genetically Engineered Oncolytic Viruses
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Herpes Simplex Virus
      • 6.1.2.2 Adenovirus
      • 6.1.2.3 Vaccinia Virus
    • 6.1.3 Market Forecast
  • 6.2 Oncolytic Wild-Type Viruses
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Reovirus
      • 6.2.2.2 Newcastle Disease Virus
      • 6.2.2.3 Vesicular Stomatitis Virus
    • 6.2.3 Market Forecast

7 Market Breakup by Application

  • 7.1 Solid Tumors
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Breast Cancer
      • 7.1.2.2 Prostate Cancer
      • 7.1.2.3 Lung Cancer
      • 7.1.2.4 Glioblastoma
    • 7.1.3 Market Forecast
  • 7.2 Melanoma
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 Hematological Malignancies
      • 7.2.2.2 Lymphoma
      • 7.2.2.3 Leukemia
      • 7.2.2.4 Myeloma
    • 7.2.3 Market Forecast

8 Market Breakup by End Use

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Specialty Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Cancer Research Institute
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Amgen Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Dnatrix Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Genelux Corporation
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Lokon Pharma AB
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Replimune Group Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Rigvir Ltd.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Sorrento Therapeutics
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
    • 14.3.8 Takara Bio Inc. (Takara Holdings Inc.)
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
    • 14.3.9 Targovax
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 TILT Biotherapeutics Ltd
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
    • 14.3.11 Transgene SA
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
    • 14.3.12 Vyriad
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report

Product Code: SR1323A103_Report

List of Figures

  • Figure 1: Global: Oncolytic Virus Therapies Market: Major Drivers and Challenges
  • Figure 2: Global: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2017-2022
  • Figure 3: Global: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 4: Global: Oncolytic Virus Therapies Market: Breakup by Virus Type (in %), 2022
  • Figure 5: Global: Oncolytic Virus Therapies Market: Breakup by Application (in %), 2022
  • Figure 6: Global: Oncolytic Virus Therapies Market: Breakup by End Use (in %), 2022
  • Figure 7: Global: Oncolytic Virus Therapies Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Oncolytic Virus Therapies (Genetically Engineered Oncolytic Viruses) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Oncolytic Virus Therapies (Genetically Engineered Oncolytic Viruses) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Oncolytic Virus Therapies (Oncolytic Wild-Type Viruses) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Oncolytic Virus Therapies (Oncolytic Wild-Type Viruses) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Oncolytic Virus Therapies (Solid Tumors) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Oncolytic Virus Therapies (Solid Tumors) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Oncolytic Virus Therapies (Melanoma) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Oncolytic Virus Therapies (Melanoma) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Oncolytic Virus Therapies (Hospitals) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Oncolytic Virus Therapies (Hospitals) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Oncolytic Virus Therapies (Specialty Clinics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Oncolytic Virus Therapies (Specialty Clinics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Oncolytic Virus Therapies (Cancer Research Institute) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Oncolytic Virus Therapies (Cancer Research Institute) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: North America: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: North America: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: United States: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: United States: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Canada: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Canada: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: Asia-Pacific: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: Asia-Pacific: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: China: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: China: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Japan: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Japan: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: India: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: India: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: South Korea: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: South Korea: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Australia: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Australia: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: Indonesia: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: Indonesia: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: Others: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: Others: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Europe: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Europe: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: Germany: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: Germany: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: France: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: France: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: United Kingdom: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: United Kingdom: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: Italy: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: Italy: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: Spain: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: Spain: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Russia: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Russia: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Others: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Others: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: Latin America: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: Latin America: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: Brazil: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: Brazil: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Mexico: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Mexico: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Others: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Others: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Middle East and Africa: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Middle East and Africa: Oncolytic Virus Therapies Market: Breakup by Country (in %), 2022
  • Figure 70: Middle East and Africa: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 71: Global: Oncolytic Virus Therapies Industry: SWOT Analysis
  • Figure 72: Global: Oncolytic Virus Therapies Industry: Value Chain Analysis
  • Figure 73: Global: Oncolytic Virus Therapies Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Oncolytic Virus Therapies Market: Key Industry Highlights, 2022 & 2028
  • Table 2: Global: Oncolytic Virus Therapies Market Forecast: Breakup by Virus Type (in Million US$), 2023-2028
  • Table 3: Global: Oncolytic Virus Therapies Market Forecast: Breakup by Application (in Million US$), 2023-2028
  • Table 4: Global: Oncolytic Virus Therapies Market Forecast: Breakup by End Use (in Million US$), 2023-2028
  • Table 5: Global: Oncolytic Virus Therapies Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Oncolytic Virus Therapies Market: Competitive Structure
  • Table 7: Global: Oncolytic Virus Therapies Market: Key Players
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!